1. Accueil >
  2. Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B >
Nasdaq

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

07-11-2017 
Spark Therapeutics to receive up to an additional $25 million per terms of amendment